

Meltem Ocak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2019060/publications.pdf>

Version: 2024-02-01

37
papers

1,355
citations

516710

16
h-index

361022

35
g-index

37
all docs

37
docs citations

37
times ranked

1878
citing authors

#	ARTICLE	IF	CITATIONS
1	EANM guideline on quality risk management for radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3353-3364.	6.4	11
2	Theranostic radiopharmacy for the nuclear medicine and molecular imaging. , 2022, , 235-242.		0
3	Almost Complete Response with a Single Administration ²²⁵Ac-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary. Molecular Imaging and Radionuclide Therapy, 2022, 31, 139-141.	0.7	2
4	Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT. Annals of Nuclear Medicine, 2021, 35, 900-915.	2.2	18
5	[⁶⁸ Ga]DOTA-FAPI-04 PET/CT imaging in a case of a signet ring cell carcinoma of stomach. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4523-4524.	6.4	4
6	Recent Developments of Radiopharmaceuticals for Neuroendocrine Tumor Imaging and Therapy. , 2021, 7, 331-338.		0
7	Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria. Nuclear Medicine Communications, 2020, 41, 759-767.	1.1	16
8	Performance of F-18 Fluorocholine PET/CT for Detection of Hyperfunctioning Parathyroid Tissue in Patients with Elevated Parathyroid Hormone Levels and Negative or Discrepant Results in conventional Imaging. Korean Journal of Radiology, 2020, 21, 236.	3.4	17
9	Post-therapy imaging of ²²⁵ Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2711-2712.	6.4	15
10	The Role of ⁶⁸ Ga-PSMA PET/CT Scan In Patients with Prostate Adenocarcinoma who Underwent Radical Prostatectomy. Urology Journal, 2020, 18, 58-65.	0.4	2
11	⁶⁴ Cu-Labeled Phosphonate Cross-Bridged Chelator Conjugates of c(RGDyK) for PET/CT Imaging of Osteolytic Bone Metastases. Cancer Biotherapy and Radiopharmaceuticals, 2018, 33, 74-83.	1.0	9
12	¹⁷⁷ Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours. Nuclear Medicine Communications, 2018, 39, 789-796.	1.1	53
13	ESTIMATION OF THE ORGAN ABSORBED DOSES AND EFFECTIVE DOSE FROM ⁶⁸ Ga-PSMA-11 PET SCANâ€. Radiation Protection Dosimetry, 2018, 182, 518-524.	0.8	8
14	The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. Nuclear Medicine Communications, 2017, 38, 149-155.	1.1	32
15	The accuracy of ⁶⁸ Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1806-1812.	6.4	89
16	The role of ⁶⁸ Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma. Nuclear Medicine Communications, 2017, 38, 76-83.	1.1	11
17	Preclinical Evaluation of ¹⁸ F-ML-10 to Determine Timing of Apoptotic Response to Chemotherapy in Solid Tumors. Molecular Imaging, 2017, 16, 153601211668594.	1.4	14
18	¹⁷⁷ Lu-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry. Molecular Imaging and Radionuclide Therapy, 2017, 26, 62-68.	0.7	53

#	ARTICLE	IF	CITATIONS
19	Normal distribution pattern and physiological variants of ⁶⁸ Ga-PSMA-11 PET/CT imaging. Nuclear Medicine Communications, 2016, 37, 1169-1179.	1.1	126
20	Preparation and <i>in-vivo</i> evaluation of dimenhydrinate buccal mucoadhesive films with enhanced bioavailability. Drug Development and Industrial Pharmacy, 2016, 42, 916-925.	2.0	18
21	Evaluation of PSMA PET/CT imaging using a ⁶⁸ Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nuclear Medicine Communications, 2015, 36, 582-587.	1.1	125
22	Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model. Molecular Pharmaceutics, 2015, 12, 542-553.	4.6	27
23	Pre-therapeutic dosimetry of normal organs and tissues of ¹⁷⁷ Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1976-1983.	6.4	166
24	FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 556-564.	6.4	57
25	⁶⁸ Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1461-1462.	6.4	127
26	Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. Nuclear Medicine Communications, 2013, 34, 1084-1089.	1.1	22
27	Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers. Nuclear Medicine Communications, 2013, 34, 1190-1195.	1.1	5
28	Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours. Nuclear Medicine Communications, 2013, 34, 727-732.	1.1	14
29	The Diagnostic Efficiency of ^{99m} Tc-EDDA/HYNIC-Octreotate SPECT-CT in Comparison with ¹¹¹ In-Pentetreotide in the Detection of Neuroendocrine Tumours. Molecular Imaging and Radionuclide Therapy, 2013, 22, 76-84.	0.7	11
30	The different distribution patterns of FDG and FDG-labelled WBC in inflammatory and infectious lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1660-1661.	6.4	4
31	Comparison of ⁶⁸ Ga-DOTATATE and ⁶⁸ Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1271-1277.	6.4	119
32	Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a ¹⁷⁷ Lu-DOTA-minigastrin derivative. Nuclear Medicine and Biology, 2011, 38, 171-179.	0.6	21
33	Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system. Nuclear Medicine Communications, 2011, 32, 887-895.	1.1	33
34	Intraoperative Localization of Recurrent Medullary Carcinoma of the Thyroid Using Tc-99m HYNIC-TATE and a Surgical Gamma Probe. Clinical Nuclear Medicine, 2011, 36, 831-833.	1.3	2
35	Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1426-1435.	6.4	70
36	Impurity in ⁶⁸ Ga-Peptide Preparation Using Processed Generator Eluate. Journal of Nuclear Medicine, 2010, 51, 495.1-495.	5.0	11

#	ARTICLE	IF	CITATIONS
37	Cyclic Minigastrin Analogues for Gastrin Receptor Scintigraphy with Technetium-99m: Preclinical Evaluation. Journal of Medicinal Chemistry, 2009, 52, 4786-4793.	6.4	43